A new clinical trial involving insulin aspart was registered on November 5, 2026. The study, titled "Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart," is listed under identifier NCT07918898.
This is a Phase 1 trial designed to compare pharmacokinetic and pharmacodynamic characteristics, along with safety, between the combined GZR101-80 injection and separately administered simultaneous doses of GZR33 injection and insulin aspart.
As of the listed date, the trial status is "not yet recruiting." No participants have been enrolled and no results have been posted. The trial record does not provide additional details on timelines, enrollment targets, or specific outcome measures beyond the comparison described in the title.
Because this is an early-phase study that has not yet begun recruitment, no safety or efficacy conclusions can be drawn at this time. Further updates would be expected once recruitment begins and as the trial progresses through its stages.
Readers interested in background on insulin aspart can consult the compound overview for additional context.